Home Page
Sunlight OmnisenseTM Proves Successful in Detecting the Effect of Treatment for Osteoporosis
Rehovot, Israel (January 1, 2000) Results of a recently concluded study suggest that treatment monitoring of osteoporosis may now be possible. The Sunlight OmnisenseTM, an ultrasound-based device developed by Sunlight Ultrasound Technologies, has demonstrated its effectiveness in discriminating between patients taking Hormone Replacement Therapy (HRT) and a non-treated control group.

HRT is administered to millions of post-menopausal women to counter bone loss due to estrogen depletion. The study shows that the Omnisense is even more effective than traditional Dual X-ray Absorptiometry (DXA) devices at detecting early bone changes due to treatment.

The study was conducted by K.M. Knapp of the Osteoporosis Unit at Guy’s Hospital in London, UK. Using Sunlight Omnisense and DXA, Dr. Knapp measured two groups of women, one being treated with Hormone Replacement Therapy for a minimum of one year and another non-treated control group.

The results, using Omnisense’s multi-site capabilities, show significant differences at the radius and tibia measurements between the subjects being treated with HRT and the control group.

The higher SOS values of the women undergoing HRT treatment indicate a positive result of the therapy. DXA-measured results did not reach statistical significance.

Omnisense calculates Speed of Sound (SOS) measurements to assess bone strength. Speed of Sound measures the speed of ultrasonic waves being axially transmitted through the patient's bone. "Omnisense’s high accuracy may be due in part to the fact that it takes into account several bone properties such as mineral density, elasticity, cohesiveness and micro-structure," stated Dr. Irit Yaniv, Sunlight's Vice President and Medical Director, "while DXA determines Bone Mineral Density (BMD) by measuring only the mineral content of the bone."